For example, if a patient is diagnosed with a CK20+, CDX2+, CK7– adenocarcinoma with liver and peritoneal metastases, both the immunohistologic profile and the distribution of metastatic sites is in tune with colorectal cancer, and treatment should be administered according to protocols for metastatic colorectal cancer (45–47). This evidence concerns the gene CDX2 and metastatic colorectal cancer.